Literature DB >> 27215360

Complications of Sedation in Critical Illness: An Update.

Jan Foster1.   

Abstract

Sedation is a necessary component of care for the critically ill. Oversedation, however, is associated with immediate complications and long-term problems, termed post-intensive care unit syndrome. It also contributes to unnecessary costs of care. This article describes the physical, functional, psychiatric, and cognitive complications of oversedation, and multiple research-based strategies that minimize complications.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complications; Costs; ICU-acquired weakness; Post-ICU syndrome; Sedation

Mesh:

Substances:

Year:  2016        PMID: 27215360     DOI: 10.1016/j.cnc.2016.02.003

Source DB:  PubMed          Journal:  Crit Care Nurs Clin North Am        ISSN: 0899-5885            Impact factor:   1.326


  4 in total

1.  Dosing for Fentanyl Infusion in Obese Children: Just Because It's What We Have Always Done Doesn't Mean It Is Right.

Authors:  Sin Yin Lim; Sukyung Woo; Jamie L Miller; Teresa V Lewis; Emilie D Henry; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2018 May-Jun

2.  Daptomycin Pharmacokinetics in Adolescents Undergoing Hemodialysis and Peritoneal Dialysis: A Case Series With Pharmacokinetic Modeling.

Authors:  Sin Yin Lim; Teresa Lewis; Sukyung Woo; Martin Turman; David W A Bourne; Michael E Burton; Pornpimol Rianthavorn
Journal:  J Pediatr Pharmacol Ther       Date:  2021-02-15

3.  Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity.

Authors:  Jacqueline G Gerhart; Fernando O Carreño; Jennifer L Ford; Andrea N Edginton; Eliana M Perrin; Kevin M Watt; William J Muller; Andrew M Atz; Amira Al-Uzri; Paula Delmore; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-05-02

Review 4.  ICU-acquired weakness.

Authors:  Ilse Vanhorebeek; Nicola Latronico; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2020-02-19       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.